Elizabeth Whittington

Two drugs fail to get FDA approval for prostate cancer prevention.

The Healthcareandyou.org website is dedicated to helping people make sense of the new healthcare law.

Regional lymph node radiation could benefit certain patients.

Updates from the 2011 annual meeting of the American Society of Clinical Oncology.

Melanoma studies with Yervoy and vemurafenib show benefit in advanced disease.

Aromasin (exemestane) provides alternative option for postmenopausal women in breast cancer prevention.

Latest study results on PARP inhibitor iniparib disappointing, but may be helpful in second-line therapy.

Avastin appears to reduce relative risk of disease progression in recurring ovarian cancer.

FDA approved Zytiga (abiraterone) to treat metastatic hormone-resistant prostate cancer.